We’re keeping our fingers crossed for a new treatment for X-linked hypophosphatemia (XLH) that is being considered by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2022. The PBAC has opened its consumer comments portal so we’re encouraging all members of our XLH community to share their story. Fingers crossed!
The Standing Committee on Health, Aged Care and Sport has recently tabled its report in the Australian Parliament – The New Frontier: Delivering better health to all Australians. XLH Australia is a strong advocate for the patient voice and we are working toward better access to new medications for all Australians. We were delighted to provide a witness statement as